

Sepideh Dashti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8389958/publications.pdf>

Version: 2024-02-01

24
papers

322
citations

840776

11
h-index

940533

16
g-index

24
all docs

24
docs citations

24
times ranked

393
citing authors

#	ARTICLE	IF	CITATIONS
1	The HOTTIP (HOXA transcript at the distal tip) lncRNA: Review of oncogenic roles in human. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110158.	5.6	42
2	TINCR: An lncRNA with dual functions in the carcinogenesis process. <i>Non-coding RNA Research</i> , 2020, 5, 109-115.	4.6	29
3	Expression analysis of vimentin and the related lncRNA network in breast cancer. <i>Experimental and Molecular Pathology</i> , 2020, 115, 104439.	2.1	25
4	In silico identification of MAPK14-related lncRNAs and assessment of their expression in breast cancer samples. <i>Scientific Reports</i> , 2020, 10, 8316.	3.3	23
5	A review on the role of oncogenic lncRNA OIP5-AS1 in human malignancies. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111366.	5.6	19
6	Assessment of the expression pattern of mTOR-associated lncRNAs and their genomic variants in the patients with breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 22044-22056.	4.1	18
7	An in-silico method leads to recognition of hub genes and crucial pathways in survival of patients with breast cancer. <i>Scientific Reports</i> , 2020, 10, 18770.	3.3	18
8	The role of long non-coding RNA CASC2 in the carcinogenesis process. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110202.	5.6	17
9	Expression profile of lncRNAs and miRNAs in esophageal cancer: Implications in diagnosis, prognosis, and therapeutic response. <i>Journal of Cellular Physiology</i> , 2020, 235, 9269-9290.	4.1	17
10	PCAT1: An oncogenic lncRNA in diverse cancers and a putative therapeutic target. <i>Experimental and Molecular Pathology</i> , 2020, 114, 104429.	2.1	12
11	BCYRN1: An oncogenic lncRNA in diverse cancers. <i>Pathology Research and Practice</i> , 2021, 220, 153385.	2.3	12
12	Mutation analysis of SLC3A1 and SLC7A9 genes in patients with cystinuria. <i>Urolithiasis</i> , 2015, 43, 447-453.	2.0	11
13	Deleted in lymphocytic leukemia 2 (DLEU2): An lncRNA with dissimilar roles in different cancers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111093.	5.6	11
14	X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 690522.	3.7	11
15	Associations between XRCC3 Thr241Met polymorphisms and breast cancer risk: systematic-review and meta-analysis of 55 case-control studies. <i>BMC Medical Genetics</i> , 2019, 20, 79.	2.1	10
16	Expression analysis of NF- κ B interacting long noncoding RNAs in breast cancer. <i>Experimental and Molecular Pathology</i> , 2020, 112, 104359.	2.1	9
17	HOX transcript antisense RNA: An oncogenic lncRNA in diverse malignancies. <i>Experimental and Molecular Pathology</i> , 2021, 118, 104578.	2.1	9
18	Gene expression of indoleamine and tryptophan dioxygenases and three long non-coding RNAs in breast cancer. <i>Experimental and Molecular Pathology</i> , 2020, 114, 104415.	2.1	8

#	ARTICLE	IF	CITATIONS
19	Expression of brain-derived neurotrophic factor (BDNF) and its naturally occurring antisense in breast cancer samples. <i>Meta Gene</i> , 2019, 19, 69-73.	0.6	7
20	Humoral immune responses against cancer-testis antigens in human malignancies. <i>Human Antibodies</i> , 2019, 27, 237-240.	1.5	5
21	Cancer-testis antigens: An update on their roles in cancer immunotherapy. <i>Human Antibodies</i> , 2019, 27, 171-183.	1.5	3
22	Assessment of anti-cancer effects of koenimbine on colon cancer cells. <i>Human Antibodies</i> , 2020, 28, 185-190.	1.5	3
23	Expression analysis of growth arrest specific 8 and its anti-sense in breast cancer tissues. <i>Experimental and Molecular Pathology</i> , 2020, 114, 104414.	2.1	2
24	Cellular immune responses against cancer-germline genes in cancers. <i>Human Antibodies</i> , 2020, 28, 57-64.	1.5	1